AMOEBA (EPA:ALMIB) - AMOEBA: WITH 8 RESEARCH PARTNERSHIPS IN BIOCONTROL, AMOEBA CONFIRMS A NEW DEVELOPMENT PHASE

Transparency directive : regulatory news

29/04/2020 08:00

PRESS RELEASE

WITH 8 RESEARCH PARTNERSHIPS IN BIOCONTROL,

AMOEBA CONFIRMS A NEW DEVELOPMENT PHASE

Chassieu (France), april 29, 2020 - AMOEBA (FR0011051598 - AMEBA), producer of
a biological biocide capable of eliminating the risk in water and human wounds,
and of a biocontrol product for plant protection, still in the testing phase,
unveils its strategic ambitions for its biocontrol activity and specifies the
future key stages of its new development phase.

A new phase of large-scale multi-partner tests

The results published by Amoeba in July 2019, demonstrating the amoeba lysate
efficacy against vine downy mildew, potato late blight and bean rust, have
raised the interest of many players in the agrochemical and biosolutions
industries, who have expressed the will to carry out their own in-house tests.

Thus, eight candidates have signed Material Transfer Agreements (MTA) with
Amoéba. The purpose of these research partnerships for Amoéba consists in
providing experimental products (in various formulations) containing the amoeba
lysate Willaertia magna C2c Maky. In return, the eight agrochemical groups will
finance and carry out their own field tests across Europe to assess the
products performance in preventing diseases on different crops.

A data multiplication and a move forward on future steps to generate early
revenues.

At the end of this testing period, which runs from spring to early autumn 2020,
the candidates will send Amoeba their results. If tests are successful, further
negotiations should take place between Amoeba and the various stakeholders to
define possible milestone payments and the basis for future business relations.
Three or four partners should be selected to move to the next product
development and commercialization phase.

An upgrade of the regulatory dossier by own and partnership tests

Amoeba will continue its own field tests in different market segments:
specialty crops (vine, tomato, vegetable crops) and field crops (cereals,
soybean, beet, potato). The targeted diseases (mildew, rust, septoria, fusarium
and cercosporia) are among those that cause significant yield reductions for
farmers.

This new evaluation phase for 2020, in the field or in climatic chambers, on
its own or in partnership, carried out on 3 continents and 11 countries, will
represent a total of more than 145 tests, among which 75 for the company.
Results obtained will complete and enrich the regulatory dossier, which
continues to be filed by Amoéba.

Amoéba arranges for obtaining the substance approval with the submission of
the regulatory dossiers by the end of May in Europe and July in the United
States. The partners will then take charge of the marketing authorizations
(MA). The first marketing authorizations could be issued in 2022 in the United
States and 2024 in Europe.

A validated financing and a continuation of activity despite the current
sanitary crisis

The tests, carried out by Amoeba, are financed through the new OCA (convertible
bond) issue contract with Nice & Green of EUR6.240 million. Intended to ensure
the continuity of operations until August 2021, this financing gives to Amoeba
the necessary means to continue its activity, particularly in terms of
regulatory files (biocontrol and biocide) and R&D until the first commercial
revenues.
"Ten years ago, Amoeba was born from the discovery of the unique properties of
the amoeba Willaertia magna C2c Maky. Driven by a desire to offer alternative
solutions to all-chemicals, we developed our lysate for application in
biocontrol. The first tests, in climatic chambers and in the field, validated
our research and development efforts. The strategy implemented over the past
year to extend research to third-party partnerships has been successful: no
less than 8 agreements have just been signed with key players in the
agrochemical industry. This new phase of strategic development in biocontrol
enables us to both enrich our biocontrol regulatory dossiers to be filed in
Europe and the United States and prepare for the marketing of biosolutions
worldwide. These decisive progresses in biocontrol do not prevent us from
advancing in parallel in the processing of our biocidal dossier which still
keeps its full potential." explains Fabrice Plasson, Chairman and CEO of
Amoéba

About AMOEBA:

Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.
Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on the compartment C of Euronext
Paris. The Company is a member of the BPIfrance Excellence network and is
eligible for the PEA-PME SME equity savings plan setup. More information on
www.amoeba-biocide.com.
(1) : Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2) : Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies,
" Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:
Amoéba
Valérie FILIATRE
General Manager
+33 (0)4 26 69 16 00
valerie.filiatre@amoeba-biocide.com

Investors and Media Relations
Grégory BOSSON / Mathieu CALLEUX
Agence Calyptus
+33(0)1 53 65 37 90
gregory.bosson@calyptus.net

Disclaimer

This press release contains certain forward-looking statements concerning
AMOEBA which are based on its own assumptions and hypothesis and on information
that are available to us. However, AMOEBA gives no assurance that the estimates
contained in such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the reference
document of AMOEBA filed with the French Financial Markets Authority (Autorité
des Marchés Financiers) on April 25, 2019 under number D19-0383 and the
prospectus approved by the AMF on january 16, 2020 under number 20-011 (a copy
of which is available on www.amoeba-biocide.com). The forward-looking
statements contained in this press release are also subject to risks not yet
known to AMOEBA or not currently considered material by AMOEBA. The occurrence
of all or part of such risks could cause actual results, financial conditions,
performance or achievements of AMOEBA to be materially different from such
forward-looking statements.

AMOEBA's latest news

28/03/2024 18:30

AMOEBA (EPA:ALMIB) - AMOEBA: WITH 8 RESEARCH PARTNERSHIPS IN BIOCONTROL, AMOEBA CONFIRMS A NEW DEVELOPMENT PHASE

Transparency directive : regulatory news

AMOEBA's latest news

Other stories